 Hui Yu
Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B7-H1 Antigen | 7 | 2020 | 243 | 2.170 |
Why?
| | Lung Neoplasms | 16 | 2020 | 2664 | 1.430 |
Why?
| | Small Cell Lung Carcinoma | 5 | 2020 | 121 | 0.810 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2020 | 1188 | 0.770 |
Why?
| | ErbB Receptors | 7 | 2020 | 635 | 0.580 |
Why?
| | In Situ Hybridization | 2 | 2016 | 318 | 0.500 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 104 | 0.460 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 644 | 0.390 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2018 | 58 | 0.380 |
Why?
| | RNA, Messenger | 3 | 2018 | 2820 | 0.370 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1468 | 0.320 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2018 | 881 | 0.290 |
Why?
| | Prognosis | 6 | 2020 | 4323 | 0.280 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1321 | 0.240 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 1439 | 0.210 |
Why?
| | Immunotherapy | 3 | 2018 | 667 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 3 | 2018 | 980 | 0.190 |
Why?
| | Pyridazines | 2 | 2018 | 57 | 0.170 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 2207 | 0.170 |
Why?
| | Mutation | 4 | 2020 | 4093 | 0.160 |
Why?
| | Sclera | 1 | 2021 | 36 | 0.160 |
Why?
| | Norway | 1 | 2020 | 41 | 0.160 |
Why?
| | Gene Dosage | 2 | 2018 | 148 | 0.160 |
Why?
| | Immunohistochemistry | 4 | 2018 | 1710 | 0.160 |
Why?
| | Sweden | 1 | 2020 | 113 | 0.160 |
Why?
| | Imidazoles | 2 | 2018 | 246 | 0.160 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 254 | 0.150 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2018 | 5 | 0.140 |
Why?
| | Hyaluronan Receptors | 1 | 2018 | 105 | 0.130 |
Why?
| | Benzamides | 1 | 2018 | 224 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 382 | 0.130 |
Why?
| | Tumor Burden | 1 | 2018 | 324 | 0.130 |
Why?
| | Epoxy Compounds | 1 | 2017 | 31 | 0.130 |
Why?
| | Biomarkers | 3 | 2018 | 4283 | 0.120 |
Why?
| | Spliceosomes | 1 | 2017 | 54 | 0.120 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 49 | 0.120 |
Why?
| | Macrolides | 1 | 2017 | 69 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 211 | 0.120 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 199 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 201 | 0.120 |
Why?
| | Mutation, Missense | 1 | 2017 | 338 | 0.110 |
Why?
| | Piperazines | 1 | 2018 | 378 | 0.110 |
Why?
| | Cadherins | 1 | 2017 | 200 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2017 | 167 | 0.110 |
Why?
| | Quinazolines | 1 | 2017 | 266 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 153 | 0.110 |
Why?
| | Interferon-gamma | 1 | 2018 | 782 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 441 | 0.100 |
Why?
| | Aged | 6 | 2020 | 26125 | 0.100 |
Why?
| | Pyrazoles | 1 | 2018 | 517 | 0.100 |
Why?
| | Cell Line, Tumor | 5 | 2018 | 3537 | 0.090 |
Why?
| | Humans | 16 | 2020 | 145491 | 0.090 |
Why?
| | Adenocarcinoma | 2 | 2017 | 923 | 0.090 |
Why?
| | Cohort Studies | 2 | 2020 | 5992 | 0.090 |
Why?
| | Cisplatin | 3 | 2020 | 345 | 0.090 |
Why?
| | MicroRNAs | 1 | 2018 | 689 | 0.090 |
Why?
| | Female | 7 | 2020 | 78763 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5426 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2018 | 335 | 0.060 |
Why?
| | Male | 5 | 2020 | 72817 | 0.060 |
Why?
| | Prospective Studies | 1 | 2016 | 8039 | 0.050 |
Why?
| | Porosity | 1 | 2021 | 95 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2018 | 2499 | 0.040 |
Why?
| | Etoposide | 1 | 2020 | 168 | 0.040 |
Why?
| | Sirolimus | 1 | 2020 | 280 | 0.030 |
Why?
| | Mice | 1 | 2016 | 18338 | 0.030 |
Why?
| | Retina | 1 | 2021 | 321 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2016 | 17269 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 335 | 0.030 |
Why?
| | Vinblastine | 1 | 2017 | 75 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 929 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 452 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2017 | 303 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2018 | 883 | 0.030 |
Why?
| | RNA Interference | 1 | 2018 | 473 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 1026 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 691 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2018 | 502 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 438 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1374 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 120 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 616 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8326 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2017 | 632 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2017 | 337 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 742 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 2015 | 188 | 0.030 |
Why?
| | Animals | 1 | 2016 | 38141 | 0.020 |
Why?
| | Ligands | 1 | 2015 | 667 | 0.020 |
Why?
| | Signal Transduction | 2 | 2018 | 5202 | 0.020 |
Why?
| | Phosphorylation | 1 | 2017 | 1707 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2030 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1769 | 0.020 |
Why?
| | Middle Aged | 3 | 2018 | 36176 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2017 | 779 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3157 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1511 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1965 | 0.020 |
Why?
| | Adult | 2 | 2018 | 40707 | 0.010 |
Why?
|
|
Yu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|